RecruitingNCT04467411

The EMBRACE Study The EMBRACE Study

Randomised Controlled Study of Physical Exercise Intervention in Breast Cancer Patients at Risk of Anthracycline-induced Cardiomyopathy:The EMBRACE Study

Sponsor

University of Aberdeen

Enrollment

70 participants

Start Date

Feb 1, 2020

Study Type

OBSERVATIONAL

Conditions

Breast Cancer

Summary

Cardiomyopathy is a condition that affects the heart muscle, whereby it becomes enlarged, thick or rigid. When the heart muscle becomes involved, it affects the pumping action of the heart. This condition can affect as many as 10% of all patients after undergoing anthracycline cancer drug therapy and unfortunately carries the worst prognosis of all cardiomyopathies. To date, there is no effective intervention that will prevent a patient from developing this condition. The research conducted will look to see if an energy imbalance in the heart predates the onset of detrimental changes to the pumping function of the heart, if this is detected then we can act earlier to prevent the pumping function deteriorating.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using a special type of heart MRI scan to monitor heart function in breast cancer patients who are about to start chemotherapy with anthracyclines — drugs known to sometimes cause heart damage. Researchers want to detect early signs of heart toxicity so it can be managed before serious damage occurs. **You may be eligible if:** - You have been diagnosed with breast cancer and are scheduled to start your first cycle of anthracycline-based chemotherapy - You are willing and able to give informed consent - Healthy volunteers of a similar age and sex are also being recruited for comparison **You may NOT be eligible if:** - You have a pacemaker, implantable defibrillator, or other device that makes MRI unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Cardiovascular Research Facility

Aberdeen, Aberdeenshire, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04467411

Related Trials

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

NCT034128771 location

Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast

NCT061297472 locations

A Randomized Two-Arm Proof of Concept Study Testing A Novel Approach to Exercise Promotion Based on Affect-regulation

NCT062589931 location

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

NCT045238571 location

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

NCT0560144010 locations